By Danny Sullivan – Longevity.Technology
Rejuvenation Technologies is targeting longevity and age-related disease with telomerase-based mRNA therapies.
For the past five years, Silicon Valley biotech Rejuvenation Technologies has been quietly working on a therapeutic platform to extend telomeres in the human body, with the goal of boosting longevity and healthspan. Yesterday, the company emerged from stealth with a healthy seed funding round of $10.6 million, led by Khosla Ventures.
Click here to view the full article
